ebronucimab   Click here for help

GtoPdb Ligand ID: 13786

Synonyms: AK-102 | AK102 | inusimab
Approved drug
ebronucimab is an approved drug
Compound class: Antibody
Comment: Ebronucimab (AK-102) is a subcutaneous fully human anti-proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibody. It blocks binding between circulating PCSK9 and the LDL receptor on hepatocytes. This reduces LDL receptor degradation, thus increasing the number of LDL receptors on cells, and effectively increasing hepatic removal LDL cholesterol from the circulation. Ebronucimab was developed for patients at high risk for cardiovascular disease when lipid-lowering cannot be achieved with statins or statins + ezetimibe.
Bioactivity Comments
We have been unable to find quantitative data for the binding of the antibody to its primary target.
Selectivity at enzymes
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
proprotein convertase subtilisin/kexin type 9 Primary target of this compound Hs Antibody Binding - - -
⤷